Arcutis Biotherapeutics, Inc. (ARQT) — SEC Filings
Arcutis Biotherapeutics, Inc. (ARQT) — 39 SEC filings. Latest: 4 (May 6, 2026). Includes 10 8-K, 10 SC 13G/A, 6 10-Q.
View Arcutis Biotherapeutics, Inc. on SEC EDGAR
Overview
Arcutis Biotherapeutics, Inc. (ARQT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Arcutis Biotherapeutics, Inc. filed an 8-K on December 8, 2025, reporting on the departure of Director Michael J. Smith and the election of new director, Dr. David J. Apfel, effective December 3, 2025. The filing also disclosed compensatory arrangements for certain officers and included financial st
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 33 neutral, 2 mixed. The dominant filing sentiment for Arcutis Biotherapeutics, Inc. is neutral.
Filing Type Overview
Arcutis Biotherapeutics, Inc. (ARQT) has filed 1 4, 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 1 10-Q/A, 1 SC 13D/A, 6 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of ARQT's 22 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $246,569,000 |
| Net Income | $7,410,000 |
| EPS | $0.06 |
| Debt-to-Equity | 1.35 |
| Cash Position | $47,120,000 |
| Operating Margin | -12.4% |
| Total Assets | $370,977,000 |
| Total Debt | $108,498,000 |
Key Executives
- Michael J. Smith
- Dr. David J. Apfel
- David M. M. Clapper
- Michael J. Miller
- Scott B. Stein
- Dr. Patrick Mooney
- James N. Topper
- Patrick J. Heron
- Steve R. Bailey
- David Rosen
Industry Context
Arcutis Biotherapeutics operates in the competitive dermatology and immunology sector, focusing on treatments for inflammatory skin conditions. The market is characterized by significant R&D investment, stringent regulatory oversight, and the need for innovative therapies to address unmet patient needs. Key trends include the development of novel drug delivery systems and targeted therapies.
Top Tags
institutional-ownership (6) · financials (4) · biotech (4) · corporate-action (3) · 10-Q (3) · SC-13G (3) · corporate-governance (2) · executive-compensation (2) · Biotechnology (2) · Dermatology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue, Net (Q3 2025) | $99.219M | Increased from $44.755M in Q3 2024, a 121.7% increase. |
| Net Income (Q3 2025) | $7.410M | Turnaround from a net loss of $41.537M in Q3 2024. |
| Total Revenues (Nine Months 2025) | $246.569M | Increased from $125.182M in Nine Months 2024, a 97% increase. |
| Accumulated Deficit (September 30, 2025) | $1,155.5M | Indicates significant historical losses despite recent quarterly profit. |
| Cash and Cash Equivalents (September 30, 2025) | $47.120M | Decreased from $71.335M at December 31, 2024, highlighting cash burn. |
| Net Cash Used in Operating Activities (Nine Months 2025) | $31.810M | Reduced from $111.410M in Nine Months 2024, showing improved operational efficiency. |
| Diluted EPS (Q3 2025) | $0.06 | Positive EPS compared to -$0.33 in Q3 2024. |
| Common Stock Shares Outstanding (September 30, 2025) | 120,288,146 | Increased from 117,848,033 at December 31, 2024, due to stock options and RSU vesting. |
| Q2 2025 Net Loss | $78.9M | Increased from $65.4M in Q2 2024, indicating widening losses. |
| Six-Month Net Loss (2025) | $156.3M | Wider than $129.8M in the prior year, showing sustained losses. |
| Accumulated Deficit | $1.56B | Increased from $1.40B at year-end 2024, highlighting significant historical losses. |
| Total Stockholders' Equity | $305.5M | Decreased from $461.8M at year-end 2024, reflecting capital erosion. |
| Shares Issued | 1.2M | Contributed to a $15.7M increase in additional paid-in capital. |
| SEC File Number | 001-39186 | Identifies the company's filing history |
| IRS Employer Identification Number | 81-2974255 | Tax identification for the company |
Forward-Looking Statements
- {"claim":"Arcutis Biotherapeutics' stock price may see increased investor interest due to Rubric Capital's significant stake.","entity":"Arcutis Biotherapeutics, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Arcutis Biotherapeutics, Inc. (ARQT)?
Arcutis Biotherapeutics, Inc. has 39 recent SEC filings from Jan 2024 to May 2026, including 10 8-K, 10 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ARQT filings?
Across 39 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Arcutis Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Arcutis Biotherapeutics, Inc. (ARQT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Arcutis Biotherapeutics, Inc.?
Key financial highlights from Arcutis Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ARQT?
The investment thesis for ARQT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Arcutis Biotherapeutics, Inc.?
Key executives identified across Arcutis Biotherapeutics, Inc.'s filings include Michael J. Smith, Dr. David J. Apfel, David M. M. Clapper, Michael J. Miller, Scott B. Stein and 5 others.
What are the main risk factors for Arcutis Biotherapeutics, Inc. stock?
Of ARQT's 22 assessed filings, 1 were flagged high-risk, 9 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Arcutis Biotherapeutics, Inc.?
Recent forward-looking statements from Arcutis Biotherapeutics, Inc. include guidance on {"claim":"Arcutis Biotherapeutics' stock price may see increased investor interest due to Rubric Capital's significant s.